• 1. Breast Center, The 4S1 Hospital of Hebei Medical University, Shijiazhuang 050000, P. R. China;
  • 2. Hebei University of Chinese Medicine, Shijiazhuang 050000, P. R. China;
  • 3. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, P. R. China;
  • 4. Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang 050004, P. R. China;
  • 5. Wuhan University School of Medicine, Wuhan 430071, P. R. China;
  • 6. Hubei Provincial Hospital of TCM, Wuhan 430061, P. R. China;
  • 7. Guangzhou Panyu District Qishan Hospital, Guangzhou 511483, P. R. China;
HUANG Qiao, Email: stat_bigdata@163.com
Export PDF Favorites Scan Get Citation

Standardized treatment has promoted the standardization and normalization of clinical practice. However, when confronted with disease heterogeneity, variations in treatment response, and differences in patient values and preferences, recommendations based on average population effects often fail to adequately address whether, when, and how a given intervention should be applied or adjusted for an individual patient. With advances in multi-omics technologies, real-world research, and artificial intelligence, individualized treatment has increasingly become an important extension of evidence-based medicine toward precision decision-making. Nevertheless, the relationship between standardized and individualized treatment, the conceptual boundaries between precision medicine and individualized medicine, and the sources of individualized evidence remain to be further clarified. Within the framework of evidence-based medicine, this article examines the value and limitations of standardized treatment, clarifies the conceptual relationships surrounding individualized treatment, and summarizes the main approaches for generating individualized evidence. We argue that individualized treatment does not negate standardized treatment; rather, it builds on standardized care by incorporating patient characteristics that are identifiable, measurable, and relevant to clinical decision-making, thereby enabling dynamic adjustment of treatment goals, strategies, dosages, and follow-up plans. Future development of individualized guidelines should retain the framework of standardized recommendations while appropriately incorporating assessment of treatment-effect heterogeneity, risk–benefit trade-offs, patient preferences, and mechanisms for dynamic reassessment, so as to improve the applicability of guideline recommendations to diverse clinical contexts and individual patient needs.

Citation: LIU Lei, WANG Shichun, LIU Zhanlun, PENG Shuzhen, BI Zhengan, YAN Siyu, ZENG Liyin, WANG Yongbo, JIN Yinghui, HUANG Qiao. From average population effects to individual precision decisions: the relationship between standardization and individualized medicine within the evidence-based medicine framework. Chinese Journal of Evidence-Based Medicine, 2026, 26(10): 1206-1213. doi: 10.7507/1672-2531.202601065 Copy

Copyright ? the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    Research progress and promotion strategies for implementation sustainability from the perspective of implementation science
  • Next Article

    Methods and examples of sample size estimation for SMARTs with binary outcomes